TC
LXRX icon

TFS Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

TFS Capital’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-106,319
Closed -$1.27M – 1092
2016
Q1 		$1.27M Buy
+106,319
New +$1.11M 0.18% 186
2015
Q4 		– Sell
-22,425
Closed -$241K – 833
2015
Q3 		$241K Sell
22,425
-6,882
-23% -$75.2K 0.02% 703
2015
Q2 		$236K Buy
+29,307
New +$215K 0.02% 720
2014
Q4 		– Sell
-16,584
Closed -$164K – 1079
2014
Q3 		$164K Buy
16,584
+3,880
+31% +$41.4K 0.01% 919
2014
Q2 		$143K Buy
+12,704
New +$136K 0.01% 1012
2014
Q1 		– Sell
-23,637
Closed -$298K – 1481
2013
Q4 		$298K Sell
23,637
-9,064
-28% -$144K 0.01% 1099
2013
Q3 		$545K Buy
32,701
+5,554
+20% +$93.1K 0.02% 832
2013
Q2 		$412K Buy
+27,147
New +$413K 0.02% 984

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TFS Capital's LXRX Position: Q2 2016 in Review

TFS Capital sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2016, closing a stake of 106,319 shares — an estimated $1.27M sold.

TFS Capital first reported a position in LXRX in Q2 2013 and held it in 8 quarters. The position peaked at $1.27M in Q1 2016. 138 funds tracked by Wall St. Rank hold LXRX as of Q2 2016.

  • TFS Capital reported no remaining Lexicon Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • TFS Capital sold 106,319 Lexicon Pharmaceuticals shares in Q2 2016, an estimated $1.27M.
  • TFS Capital first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 8 quarters.
  • TFS Capital's Lexicon Pharmaceuticals position peaked at $1.27M in Q1 2016.
  • 138 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2016.

Based on TFS Capital's 13F filing for Q2 2016, filed 11 Aug 2016.